Article

Glaucoma may be neurologic disorder

A new research paradigm may move glaucoma out of the realm of eye disease and characterize it as a neurologic disorder that causes nerve cells in the brain to degenerate and die, similar to what occurs in Parkinson's and Alzheimer's diseases.

San Francisco-A new research paradigm may move glaucoma out of the realm of eye disease and characterize it as a neurologic disorder that causes nerve cells in the brain to degenerate and die, similar to what occurs in Parkinson’s and Alzheimer’s diseases.

For many years, the prevailing theory was that vision damage in patients with glaucoma was caused by abnormally high IOP. The new research paradigm focuses on the damage that occurs in retinal ganglion cells (RGCs), which connect the eye to the brain through the optic nerve.

A review in Ophthalmology by Jeffrey L Goldberg, MD, PhD, assistant professor of ophthalmology at the Bascom Palmer Eye Institute and Interdisciplinary Stem Cell Institute, University of Miami, FL, describes RGC-targeted glaucoma treatments that are either being tested in patients or are scheduled to begin clinical trials soon. These include medications injected into the eye that deliver survival and growth factors to RGCs, medications known to be useful for stroke and Alzheimer’s disease, and electrical stimulation of RGCs. Human trials of stem cell therapies are in the planning stages.

“As researchers turn their attention to the mechanisms that cause retinal ganglion cells to degenerate and die, they are discovering ways to protect, enhance, and even regenerate these vital cells,” said Dr. Goldberg. “Understanding how to prevent damage and improve healthy function in these neurons may ultimately lead to sight-saving treatments for glaucoma and other degenerative eye diseases.”

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
© 2025 MJH Life Sciences

All rights reserved.